SCHEMBL13587330

SCHEMBL13587330

[3H]c1ccc(C#Cc2ccc(C#Cc3nc4c(=O)[nH]cnc4n3C)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IP6K1 Q92551 1/20 0.39
▸ IP6K3 Q96PC2 1/20 0.39
▸ IP6K2 Q9UHH9 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ GRM4 Q14833 3/20 0.34
▸ HPRT1 P00492 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ NOS1 P29475 1/20 0.31
▸ SRC P12931 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ GRM5 P41594 1/20 0.31
▸ ATAD2 Q6PL18 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13587320 0.99 IP6K1 (0.37) IP6K1IP6K3IP6K2ADORA3ADORA2A
SCHEMBL13587316 0.90 IP6K1 (0.45) IP6K1IP6K3IP6K2ADORA3ADORA2A
SCHEMBL13587332 0.82 XDH (0.43) NOS1PNP
SCHEMBL13587324 0.81 XDH (0.43) NOS1PNP
SCHEMBL13587328 0.78 ADORA2A (0.58) ADORA3ADORA2AADORA1
SCHEMBL13587315 0.77 ADORA2A (0.59) ADORA3ADORA2AADORA1
SCHEMBL13587331 0.75 NOS1 (0.32) ADORA2AALDH1A1NOS1KDM4EHSD17B10
SCHEMBL13587318 0.73 NOS1 (0.32) ADORA2AALDH1A1NOS1KDM4EHSD17B10
SCHEMBL13587313 0.72 XDH (0.52) ADORA3ADORA2AADORA1NOS1KDM4E
SCHEMBL13587327 0.70 ALDH1A1 (0.34) ADORA3HPRT1ALDH1A1MAPK1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090299049-A1 Bicyclic Compounds and Their Use REPLIZYME LIMITED (GB) 2009-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299049-A1 Bicyclic Compounds and Their Use ERCC4, PARP1, ERCC5 IP6K1 2543/4885IP6K3 2707/4885IP6K2 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback